A male patient, aged 62 years, returns to the primary care clinic for a follow-up evaluati… — USMLE Step 3

A male patient, aged $62$ years, returns to the primary care clinic for a follow-up evaluation. He has a history of type $2$ diabetes mellitus, essential hypertension, and hyperlipidemia. Two weeks ago, his blood pressure was $154/92$ mmHg. At that time, laboratory studies demonstrated a serum creatinine of $1.1$ mg/dL, a serum potassium of $4.2$ mEq/L, and a urine albumin-to-creatinine ratio of $210$ mg/g. To address his hypertension and microalbuminuria, ramipril was initiated. Today, the patient reports feeling well with no lightheadedness, shortness of breath, or peripheral edema. His blood pressure is now $132/82$ mmHg, and his heart rate is $74$ /min. Repeat laboratory studies obtained this morning show a serum sodium of $139$ mEq/L, a serum potassium of $4.8$ mEq/L, a blood urea nitrogen of $16$ mg/dL, and a serum creatinine of $1.4$ mg/dL. Which of the following is the most appropriate next step in management?

Continue ramipril at the current doseAnswer
B
Discontinue ramipril and initiate amlodipine
C
Add spironolactone to the current regimen
D
Order bilateral renal artery duplex ultrasonography
E
Refer the patient for a percutaneous renal biopsy

Answer

Continue ramipril at the current dose

The correct answer is to continue the medication at the current dose. Angiotensin-converting enzyme (ACE) inhibitors, such as ramipril, inhibit the conversion of angiotensin I to angiotensin II. Angiotensin II normally constricts the efferent arteriole of the glomerulus. By blocking this effect, ACE inhibitors cause efferent arteriolar vasodilation, which lowers intraglomerular pressure. This is a highly desirable effect in diabetic nephropathy because it reduces protein spillage (albuminuria) and slows the progression of chronic kidney disease. However, lowering the intraglomerular pressure also mildly decreases the glomerular filtration rate (GFR), which manifests as a slight rise in serum creatinine. Guidelines establish that an initial rise in serum creatinine of up to 30% from baseline within the first few weeks of therapy is a normal and acceptable physiological response. In this patient, the creatinine increased from 1.1 mg/dL to 1.4 mg/dL (a 27% increase). Because the increase is less than 30%, his serum potassium is acceptable (<5.0 mEq/L), and his blood pressure is well controlled, the most appropriate action is to continue the current regimen and monitor.

Step-by-Step Solution

Evaluate the patient's current blood pressure compared to the previous visit.

Blood pressure has improved from 154/92 mmHg to 132/82 mmHg.

To determine the clinical efficacy of the newly initiated antihypertensive therapy.

Calculate the percentage increase in serum creatinine from baseline.

Creatinine increased from 1.1 mg/dL to 1.4 mg/dL, an absolute increase of 0.3 mg/dL, which is approximately a 27% increase.

To differentiate between an expected physiological hemodynamic change and pathological acute kidney injury.

Assess the serum potassium level for hyperkalemia.

Potassium is 4.8 mEq/L, which is within the normal range.

ACE inhibitors can decrease aldosterone secretion, leading to potentially dangerous potassium retention.

Determine the appropriate management plan based on the lab findings.

Because the creatinine bump is less than 30%, potassium is normal, and blood pressure is controlled, the therapy should be maintained.

To maximize the renoprotective benefits of the ACE inhibitor for diabetic nephropathy without compromising patient safety.

Key Concept

Patients initiated on ACE inhibitors or ARBs may experience a physiological increase in serum creatinine of up to 30% above baseline; if the increase is within this limit and hyperkalemia is absent, the medication should be continued.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic